Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$7.56 USD
-0.58 (-7.13%)
Updated May 6, 2024 04:00 PM ET
After-Market: $7.55 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for Nuvectis Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.26 | -19.09 | -12.89 | -0.01 | NA |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change from Assets/Liabilities | 1.60 | 3.82 | 1.49 | 0.01 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 4.71 | 1.71 | 1.89 | 0.00 | NA |
Net Cash From Operating Activities | -15.95 | -13.56 | -9.50 | 0.00 | NA |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 16.48 | 31.88 | 15.25 | 0.00 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -1.39 | -4.07 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 15.09 | 27.81 | 15.25 | 0.00 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -0.87 | 14.25 | 5.74 | 0.00 | NA |
Cash at Beginning of Period | 19.99 | 5.74 | 0.00 | 0.00 | NA |
Cash at End of Period | 19.13 | 19.99 | 5.74 | 0.00 | NA |
Diluted Net EPS | -1.43 | -1.51 | -3.02 | NA | NA |
Fiscal Year End for Nuvectis Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -22.26 | -15.64 | -9.76 | -4.05 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | 1.60 | 0.05 | -1.46 | -2.13 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.71 | 3.49 | 2.35 | 1.40 |
Net Cash From Operating Activities | NA | -15.95 | -12.10 | -8.86 | -4.78 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 16.48 | 15.58 | 14.44 | 0.70 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -1.39 | -1.41 | -0.97 | -0.45 |
Net Cash from Financing Activities | NA | 15.09 | 14.17 | 13.47 | 0.25 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -0.87 | 2.07 | 4.61 | -4.53 |
Cash at Beginning of Period | NA | 19.99 | 19.99 | 19.99 | 19.99 |
Cash at End of Period | NA | 19.13 | 22.06 | 24.60 | 15.47 |
Diluted Net EPS | NA | -0.41 | -0.37 | -0.38 | -0.27 |